CTI BioPharma receives $10 million milestone payment for TRISENOX®
CTI BioPharma announced it has received a $10 million milestone payment from Teva Pharmaceutical related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, and Cephalon was subsequently acquired by Teva. February 11, 2019